Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime

What Was Tested

The paper reports a study of Insulin Lispro and NPH Insulin (isophane), published as a randomized controlled trial.

To establish whether the short-acting insulin analog lispro can be successfully implemented in long-term intensive insulin therapy in type 1 diabetes, and if so, what its effects are on glycemic control and frequency and awareness of hypoglycemia.

Who Took Part

The abstract describes 56 patients taking part.

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

The design is described as randomized and parallel-group.

Random assignment meant chance, not the researchers, decided who got Insulin Lispro and who got the comparison, which limits bias.

Groups ran in parallel: each of the patients stayed in one arm throughout.

Lispro was injected at mealtime and Hum-R was given 10-40 min before meals (bedtime NPH was continued on both occasions).

With lispro, NPH was added at breakfast (approximately 70/30), lunch (approximately 60/40), and supper (approximately 80/20) (mixing percentage of lispro/NPH) to optimize premeal and bedtime blood glucose.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 1, Drug Combinations, Eating, Glycated Hemoglobin, Hypoglycemic Agents, Insulin and Insulin Lispro.

What This Means in Plain Language

The paper is a randomized and parallel-group study of Insulin Lispro and NPH Insulin (isophane) in 56 patients.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1999 (Diabetes care), a journal based in United States.

More context: the Insulin Lispro compound page and the NPH Insulin (isophane) compound page, all human trials.